In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies
In silico immunogenicity risk assessment has been an important step in the development path for many biologic therapeutics, including monoclonal antibodies. Even if the source of a given biologic is ‘fully human’, T cell epitopes that are contained in the sequences of the biologic may activate the i...
| Asıl Yazarlar: | , , , , , , , |
|---|---|
| Materyal Türü: | Makale |
| Dil: | English |
| Baskı/Yayın Bilgisi: |
Taylor & Francis Group
2024-12-01
|
| Seri Bilgileri: | mAbs |
| Konular: | |
| Online Erişim: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2333729 |